Course Information

Release date: March 26, 2026
Expiration date: March 26, 2027
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This program is supported by ARS Pharmaceuticals Operations, Inc.

PROGRAM OVERVIEW

The introduction of preventive biologic therapies has improved allergic disease control but has also created confusion about the continued need for rescue treatment. This case-based activity centers on an adolescent with multiple food allergies beginning anti-immunoglobulin E (IgE) therapy, whose family questions whether epinephrine remains necessary. Expert faculty insight will address strategies for clearly distinguishing risk reduction from emergency treatment, reinforcing the ongoing role of epinephrine, and counseling families during transitions in therapy. Learners will explore approaches to reassessing device preferences, updating emergency action plans, and supporting consistent epinephrine access across school, sports, and home environments to maintain readiness despite perceived lower risk.

Learning Objectives

TARGET AUDIENCE

This educational activity is designed for primary care, pediatric, allergy/immunology, and emergency room clinicians, as well as other healthcare providers involved in the treatment and management of anaphylaxis.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Apply evidence-based communication strategies to counsel patients and caregivers on recognizing anaphylaxis and the importance of timely epinephrine administration
Address common misconceptions and barriers that contribute to under-utilization of epinephrine, such as fear of needles, reliance on antihistamines, concerns about nasal congestion, and misunderstanding of the role of preventive therapies
Develop personalized anaphylaxis readiness plans that incorporate shared decision-making, reinforce carriage and correct use of rescue medication, and ensure alignment across home, school, and community settings

Faculty Information and Disclosures

FACULTY

Thomas B. Casale, MD
Professor of Medicine and Pediatrics
Director, Division of Allergy and Immunology
Joy McCann Culverhouse Clinical Research Center
University of South Florida
Tampa, Florida

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Thomas B. Casale, MD

Consultant: ARS Pharmaceuticals, AstraZeneca, Eli Lilly, Excellergy, Genentech, Jasper, Novartis, Pfizer, Sanofi/Regeneron

Research: National Institutes of Health, Thermo Fisher Scientific

Royalties: UpToDate

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of March 26, 2026 through March 26, 2027, participants must:

Read the learning objectives
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Internet: Stable connection
Operating Systems: Windows 10/macOS 10.14 or later recommended
Web Browser: Latest versions of Google Chrome, Microsoft Edge, or Safari recommended (other modern browsers also supported)
Plug-ins: No plug-ins required

For optimal performance and security, ensure your browser is up to date and avoid using unsupported or outdated versions.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: March 26, 2026Expiration date: March 26, 2027 Estimated time to complete activity: 15 minutes

Managing Risk for Anaphylaxis in Patient Receiving Anti-IgE Treatment for the Reduction of Allergic Reactions